Compare Hinge Health Inc. Class A Common Stock (HNGE) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs SpaceX — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while SpaceX trades at $148.88 (market cap $2.12T). The key difference: SpaceX is far larger — about 250× Hinge Health Inc. Class A Common Stock's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and SpaceX for 42 Days on average.
| HNGE | SPCX | |
|---|---|---|
Market Cap | $8.48B | $2.12T |
Volume | 879,799 | 68,438,228 |
Sector | Health | Industrials |
52-Week High | $105.14 | $202.09 |
52-Week Low | $31.17 | $108.27 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $8.10B | $2.06T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
SpaceX (SPCX) trades at $156.54, down 4.21% amid broader market weakness despite recent operational successes. Technical indicators show a bullish trend with strong institutional buying support. The company maintains robust revenue growth projections ($23B for 2026) but faces profitability challenges with negative net margins (-35.66%) and elevated valuations (P/S 72.26). Recent news highlights Starlink's expansion into wireless markets while geopolitical tensions create operational complexities.
Long-term growth prospects remain compelling given SpaceX's dominant market position and Starlink expansion, though current valuations require substantial future execution. Key risks include execution on massive capital expenditures, competitive pressures in satellite communications, and geopolitical sensitivities. Analyst consensus remains strongly bullish with a $211.43 price target representing 35% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
